
  
    
      
        Background_NNP
        Mutations_NNP in_IN 
        MYOC_NNP have_VBP been_VBN shown_VBN to_TO be_VB causative_JJ
        for_IN primary_JJ open_JJ angle_NN glaucoma_NN (_( POAG_NNP )_) [_NN 1_CD 2_CD 3_CD ]_NN ._.
        Glucocorticoids_NNP have_VBP been_VBN implicated_VBN in_IN ocular_NN hypertension_NN
        and_CC glaucoma_NN due_JJ to_TO increased_VB plasma_NN cortisol_NN levels_NNS [_NN 4_CD 5_CD
        ]_NN and_CC altered_VBN cortisol_NN metabolism_NN [_NN 6_CD 7_CD ]_NN in_IN POAG_NNP patients_NNS
        and_CC from_IN the_DT increased_VBN risk_NN of_IN developing_VBG POAG_NNP in_IN
        steroid-responsive_JJ patients_NNS [_NN 8_CD 9_CD ]_NN ._. Myocilin_NNP has_VBZ been_VBN
        shown_VBN to_TO be_VB upregulated_JJ in_IN glucocorticoid-treated_JJ human_JJ
        trabecular_NN meshwork_NN (_( TM_NNP )_) cells_NNS [_NN 10_CD 11_CD ]_NN ,_, and_CC there_EX is_VBZ
        variable_JJ evidence_NN for_IN increased_VBN 
        MYOC_NNP expression_NN in_IN glaucomatous_JJ
        individuals_NNS [_NN 12_CD 13_CD 14_CD ]_NN ._. In_IN addition_NN ,_, glaucoma_NN patients_NNS
        have_VBP a_DT higher_JJR chance_NN of_IN responding_VBG to_TO steroids_NNS than_IN
        non-glaucomatous_JJ individuals_NNS ._. However_RB ,_, an_DT extensive_JJ study_NN
        of_IN mutations_NNS in_IN the_DT proximal_NN promoter_NN and_CC coding_VBG region_NN of_IN 
        MYOC_NNP found_VBD no_DT sequence_NN polymorphisms_NNS
        associated_VBN with_IN steroid_NN responsiveness_NNS [_NN 15_CD ]_NN ._.
        Myocilin_NNP has_VBZ been_VBN shown_VBN to_TO be_VB secreted_JJ both_DT in_IN human_JJ TM_NNP
        cell_NN cultures_NNS and_CC in_IN vivo_NN in_IN aqueous_JJ humor_NN (_( AH_NNP )_) [_NN 12_CD ]_NN ._.
        Glaucomatous_NNP mutations_NNS ,_, however_RB ,_, alter_VB myocilin_NN Triton_NNP
        solubility_NN [_NN 16_CD ]_NN and_CC prevent_VB myocilin_NN from_IN being_VBG secreted_JJ
        [_NN 12_CD ]_NN ._. The_DT glycosylation_NN status_NN of_IN myocilin_NN is_VBZ somewhat_RB
        controversial_JJ ._. Several_JJ groups_NNS have_VBP shown_VBN that_DT myocilin_NN is_VBZ
        glycosylated_JJ [_NN 10_CD 16_CD 17_CD 18_CD 19_CD 20_CD 21_CD ]_NN whereas_IN one_CD group_NN
        suggests_VBZ that_DT myocilin_NN is_VBZ not_RB glycosylated_JJ [_NN 22_CD ]_NN ._. In_IN our_PRP$
        hands_NNS ,_, both_DT an_DT N-_NNP linked_VBD glycosylated_JJ (_( ≈_NN 57_CD -_: kDa_NN )_) and_CC
        unglycosylated_JJ (_( ≈_NN 55_CD -_: kDa_NN )_) form_NN of_IN myocilin_NN is_VBZ detected_VBN in_IN TM_NNP
        cell_NN culture_NN media_NNS [_NN 17_CD ]_NN and_CC aqueous_JJ humor_NN [_NN 12_CD ]_NN ._. The_DT
        basis_NN for_IN both_DT secretion_NN and_CC N-_NNP linked_VBD glycosylation_NN of_IN
        myocilin_NN is_VBZ part_NN of_IN the_DT focus_NN of_IN this_DT paper_NN ._.
        Rabbits_NNP have_VBP been_VBN successfully_RB used_VBN as_IN a_DT model_NN of_IN
        glucocorticoid-induced_JJ ocular_NN hypertension_NN [_NN 23_CD 24_CD 25_CD 26_CD 27_CD
        ]_NN ._. In_IN order_NN to_TO study_VB the_DT association_NN of_IN 
        MYOC_NNP gene_NN expression_NN with_IN
        steroid-induced_JJ ocular_NN hypertension_NN ,_, it_PRP will_MD be_VB helpful_JJ to_TO
        know_VB the_DT sequence_NN of_IN rabbit_NN myocilin_NN ._. We_PRP report_VBP here_RB the_DT
        cloning_VBG ,_, sequence_NN comparison_NN and_CC expression_NN analysis_NN of_IN
        rabbit_NN 
        MYOC_NNP ._. We_PRP show_VBP that_IN an_DT N-_NNP terminal_NN
        signal_NN peptide_NN is_VBZ necessary_JJ for_IN myocilin_NN secretion_NN and_CC we_PRP
        identify_VBP the_DT N-_NNP linked_VBD glycosylation_NN site_NN found_VBD in_IN human_JJ but_CC
        not_RB rabbit_NN myocilin_NN ._.
      
      
        Results_NNS
        
          Characterization_NNP of_IN Rabbit_NNP MYOC_NNP
          We_PRP have_VBP cloned_VBN a_DT 2_CD -_: kb_NN cDNA_NN for_IN rabbit_NN 
          MYOC_NNP that_IN encodes_NNS a_DT 490_CD amino_JJ acid_NN ,_,
          55_CD -_: kDa_NN protein_NN with_IN a_DT calculated_VBN pI_NN of_IN 5_CD ._. 25_CD (_( Fig_NNP ._. 1_LS )_) ._.
          Rabbit_NNP myocilin_NN amino_JJ acid_NN sequence_NN is_VBZ 84_CD %_NN identical_JJ to_TO
          human_JJ myocilin_NN [_NN 28_CD ]_NN and_CC highly_RB homologous_RB across_IN
          species_NNS (_( Table_NNP 2_LS )_) with_IN an_DT overall_JJ 64_CD %_NN homology_NN ._. Rabbit_NNP
          myocilin_NN is_VBZ 14_CD amino_JJ acids_NNS shorter_JJR at_IN the_DT N-_NNP terminus_JJ than_IN
          human_JJ myocilin_NN and_CC the_DT same_JJ length_NN as_IN monkey_NN [_NN 15_CD ]_NN ,_,
          mouse_NN [_NN 29_CD 30_CD ]_NN ,_, and_CC bovine_JJ [_NN 31_CD ]_NN myocilin_NN (_( Fig_NNP ._. 2_LS )_) ._. As_IN
          in_IN all_DT myocilin_NN orthologs_NNS cloned_VBN to_TO date_NN ,_, rabbit_NN myocilin_NN
          contains_VBZ a_DT leucine_NN zipper_NN motif_NN (_( aa_NN 103_CD to_TO 152_CD )_) (_( Fig_NNP ._. 2_LS )_) ._.
          A_DT potential_JJ peroxisomal_NN targeting_VBG signal_NN is_VBZ encoded_JJ on_IN
          the_DT C-_NNP terminus_JJ (_( SKI_NNP ,_, aa_NN 488_CD -_: 490_CD )_) ._. Unlike_IN human_JJ ,_, monkey_NN
          and_CC mouse_NN myoclin_NN ,_, rabbit_NN myocilin_NN does_VBZ not_RB contain_VB a_DT
          consensus_NN N-_NNP linked_VBD glycosylation_NN site_NN (_( N-X-S_NNP /_NN T_NN ;_: human_JJ ,_, aa_NN
          57_CD -_: 59_CD ;_: monkey_NN ,_, aa_NN 43_CD -_: 45_CD ;_: mouse_NN ,_, aa_NN 43_CD -_: 45_CD )_) (_( Fig_NNP ._. 2_LS )_) ._. The_DT
          nucleotide_NN sequence_NN for_IN rabbit_NN 
          MYOC_NNP reported_VBD in_IN this_DT manuscript_NN
          has_VBZ been_VBN submitted_VBN to_TO GenBank_NNP (_( AY_NNP 191317_CD )_) ._.
        
        
          Secretion_NNP of_IN Rabbit_NNP MYOC_NNP
          Rabbit_NNP ,_, monkey_NN ,_, mouse_NN and_CC bovine_JJ myocilin_NN open_JJ reading_NN
          frames_NNS begin_VBP at_IN amino_JJ acid_NN 15_CD relative_JJ to_TO human_JJ myocilin_NN ._.
          The_DT function_NN ,_, if_IN any_DT ,_, of_IN the_DT extra_JJ N-_NNP terminal_NN 14_CD aa_NN
          encoded_JJ by_IN human_JJ myocilin_NN is_VBZ not_RB presently_RB known_VBN ._. Rat_NNP
          myocilin_NN also_RB contains_VBZ an_DT extra_JJ 13_CD aa_NN N-_NNP terminal_NN sequence_NN
          [_NN 32_CD ]_NN ._. To_TO determine_VB if_IN rabbit_NN myocilin_NN is_VBZ secreted_JJ
          despite_IN the_DT absence_NN of_IN the_DT additional_JJ human-like_JJ
          N-_NNP terminal_NN 14_CD aa_NN ,_, we_PRP examined_VBD rabbit_NN aqueous_JJ humor_NN ._. We_PRP
          were_VBD able_JJ to_TO detect_VB myocilin_NN in_IN rabbit_NN aqueous_JJ humor_NN
          (_( Fig_NNP ._. 3_LS A_DT )_) ._. This_DT suggests_VBZ that_IN the_DT human_JJ N-_NNP terminal_NN 14_CD aa_NN
          is_VBZ dispensible_JJ for_IN secretion_NN and_CC that_IN the_DT rabbit_NN myocilin_NN
          sequence_NN is_VBZ sufficient_JJ to_TO direct_VB secretion_NN ._.
          Next_JJ we_PRP created_VBD a_DT human_JJ myocilin_NN expression_NN construct_VB
          where_WRB the_DT N-_NNP terminal_NN 14_CD aa_NN were_VBD deleted_VBN
          (_( pcDNA_NN 3_CD ._. hMYOC_NN ._. ΔN_NN 14_CD )_) forcing_VBG translation_NN to_TO begin_VB at_IN the_DT
          second_JJ methionine_NN codon_NN (_( Fig_NNP ._. 2_LS )_) ._. GTM_NNP 66_CD cells_NNS were_VBD chosen_VBN
          for_IN this_DT study_NN based_VBN on_IN their_PRP$ ability_NN to_TO grow_VB and_CC
          transfect_NN well_RB and_CC are_VBP a_DT glaucomatous_JJ TM_NNP cell_NN line_NN
          derived_VBN from_IN a_DT 92_CD -_: year-old_JJ female_JJ donor_NN [_NN 11_CD 17_CD ]_NN ._.
          Transfection_NNP of_IN GTM_NNP 66_CD cells_NNS with_IN the_DT N-_NNP terminal_NN deletion_NN
          mutant_JJ resulted_VBD in_IN a_DT distribution_NN pattern_NN similar_JJ to_TO
          wild-type_JJ human_JJ myocilin_NN (_( Fig_NNP ._. 3_LS B_NNP )_) ._. The_DT fact_NN that_IN we_PRP see_VBP
          no_DT discernable_JJ difference_NN in_IN the_DT relative_JJ mobility_NN
          between_IN transfected_JJ human_JJ wild-type_JJ myocilin_NN and_CC 14_CD amino_JJ
          acid_NN amino-terminal_JJ deleted_VBN myocilin_NN (_( Fig_NNP ._. 3_LS B_NNP )_) and_CC human_JJ
          vs_NNS ._. monkey_NN myocilin_NN in_IN AH_NNP (_( Fig_NNP ._. 3_LS A_DT )_) may_MD be_VB due_JJ to_TO the_DT use_NN
          of_IN small_JJ format_NN gels_NNS or_CC possibly_RB to_TO the_DT usage_NN of_IN the_DT
          second_JJ N-_NNP terminal_NN methionine_NN by_IN the_DT cell_NN for_IN synthesizing_VBG
          human_JJ myocilin_NN ,_, making_VBG human_NN and_CC monkey_NN molecular_JJ weights_NNS
          comparable_JJ ._.
          Nonetheless_RB ,_, an_DT N-_NNP terminal_NN signal_NN peptide_NN is_VBZ likely_JJ
          necessary_JJ for_IN directing_VBG synthesis_NN of_IN myocilin_NN ,_, via_IN the_DT
          ER-Golgi_NNP pathway_NN ,_, for_IN secretion_NN outside_IN the_DT cell_NN ._. To_TO
          determine_VB what_WP actually_RB constitutes_VBZ the_DT signal_NN sequence_NN
          for_IN myocilin_NN ,_, we_PRP conducted_VBD an_DT analysis_NN of_IN signal_NN peptide_NN
          cleavage_NN sites_NNS using_VBG the_DT Center_NNP for_IN Biological_NNP Sequence_NNP
          Analysis_NNP SignalP_NNP v_NN 1_CD ._. 1_LS Database_NNP
          http_NN :_: /_NN /_NN www_NN ._. cbs_NNS ._. dtu_NN ._. dk_NN /_NN services_NNS /_NN SignalP_NNP /_NN ._. A_DT signal_NN peptide_NN
          cleavage_NN site_NN was_VBD predicted_VBN to_TO exist_VB between_IN rabbit_NN aa_NN 18_CD
          and_CC 19_CD (_( human_JJ aa_NN 32_CD and_CC 33_CD )_) [_NN 33_CD ]_NN ._. We_PRP directly_RB tested_VBD
          the_DT importance_NN of_IN the_DT signal_NN peptide_NN in_IN myocilin_NN
          secretion_NN by_IN replacing_VBG the_DT first_JJ 32_CD aa_NN of_IN human_JJ myocilin_NN
          with_IN a_DT single_JJ methionine_NN (_( pcDNA_NN 3_CD ._. hMYOC_NN ._. ΔN_NN 32_CD )_) ._.
          Transfection_NNP of_IN GTM_NNP 66_CD cells_NNS with_IN pcDNA_NN 3_CD ._. hMYOC_NN ._. ΔN_NN 32_CD
          resulted_VBD in_IN intracellular_NN but_CC not_RB extracellular_NN myocilin_NN
          distribution_NN (_( Fig_NNP ._. 3_LS B_NNP )_) ._. This_DT is_VBZ the_DT result_NN expected_VBN if_IN
          the_DT signal_NN peptide_NN were_VBD necessary_JJ for_IN secretion_NN ._. This_DT
          suggests_VBZ that_IN the_DT first_JJ 18_CD aa_NN of_IN rabbit_NN myocilin_NN may_MD
          function_VB as_IN a_DT signal_NN peptide_NN and_CC are_VBP necessary_JJ for_IN
          myocilin_NN secretion_NN ._.
        
        
          Myocilin_NNP Glycosylation_NNP
          Human_JJ myocilin_NN has_VBZ been_VBN shown_VBN to_TO migrate_VB as_IN a_DT
          55_CD /_NN 57_CD -_: kDa_NN doublet_NN by_IN SDS-PAGE_NNP /_NN immunoblot_NN analysis_NN [_NN 10_CD 11_CD
          12_CD 16_CD 17_CD ]_NN ._. The_DT modification_NN accounting_NN for_IN this_DT
          molecular_JJ weight_NN difference_NN is_VBZ hypothesized_VBN to_TO be_VB due_JJ to_TO
          differential_NN glycosylation_NN ._. N-_NNP linked_VBD glycosylation_NN sites_NNS
          were_VBD predicted_VBN using_VBG the_DT Center_NNP for_IN Biological_NNP Sequence_NNP
          Analysis_NNP NetNGlyc_NNP 1_CD ._. 0_CD Prediction_NNP Server_NNP
          http_NN :_: /_NN /_NN www_NN ._. cbs_NNS ._. dtu_NN ._. dk_NN /_NN services_NNS /_NN NetNGlyc_NNP /_NN ._. Human_NNP ,_, monkey_NN
          and_CC mouse_NN myocilin_NN contain_VBP a_DT consensus_NN asparagine_NN
          (_( N_NNP )_) -_: linked_VBN glycosylation_NN site_NN (_( NES_NNP )_) near_IN the_DT N-_NNP terminus_JJ ,_,
          whereas_IN rabbit_NN ,_, rat_NN and_CC bovine_JJ code_NN for_IN SES_NNP at_IN this_DT
          position_NN (_( Fig_NNP ._. 2_LS )_) ._. Having_VBG a_DT serine_NN present_JJ at_IN this_DT
          position_NN would_MD eliminate_VB N-_NNP linked_VBD glycosylation_NN and_CC would_MD
          be_VB predicted_VBN to_TO result_VB in_IN a_DT difference_NN in_IN relative_JJ gel_NN
          mobility_NN between_IN human_JJ /_NN monkey_NN and_CC rabbit_NN myocilin_NN ._.
          To_TO test_VB this_DT hypothesis_NNS we_PRP analyzed_VBD human_JJ ,_, monkey_NN ,_, and_CC
          rabbit_NN AH_NNP myocilin_NN side-by-side_RB in_IN SDS-PAGE_NNP /_NN immunoblots_NNS ._.
          The_DT anti-human_JJ myocilin_NN antibody_NN 129_CD used_VBN in_IN these_DT
          studies_NNS (_( generated_VBN to_TO human_JJ amino_JJ acids_NNS 156_CD -_: 171_CD [_NN 12_CD 17_CD ]_NN
          )_) cross-reacts_JJ with_IN rabbit_NN and_CC monkey_NN myocilin_NN ._. With_IN
          human_NN and_CC monkey_NN myocilin_NN we_PRP see_VBP a_DT clear_JJ doublet_NN ,_, whereas_IN
          rabbit_NN myocilin_NN migrates_NNS as_IN a_DT single_JJ band_NN with_IN the_DT same_JJ
          relative_JJ mobility_NN as_IN the_DT lower_JJR band_NN of_IN human_NN and_CC monkey_NN
          myocilin_NN (_( Fig_NNP ._. 3_LS A_DT )_) ,_, suggesting_VBG that_IN the_DT asparagine_NN vs_NNS ._.
          serine_NN amino_JJ acid_NN difference_NN is_VBZ responsible_JJ for_IN the_DT
          differential_NN glycosylation_NN ._.
          To_TO directly_RB test_VB this_DT theory_NN ,_, we_PRP mutated_VBN human_JJ
          myocilin_NN amino_JJ acid_NN 57_CD from_IN Asn_NNP to_TO Ser_NNP ,_, as_IN found_VBN in_IN
          rabbit_NN myocilin_NN ._. Media_NNP and_CC cell_NN lysate_NN from_IN transfected_JJ
          GTM_NNP 66_CD cells_NNS contained_VBD a_DT single_JJ immunoreactive_JJ myocilin_NN
          band_NN that_IN migrated_JJ with_IN the_DT same_JJ relative_JJ mobility_NN as_IN the_DT
          lower_JJR wt_NN myocilin_NN band_NN (_( Fig_NNP ._. 3_LS B_NNP )_) ._. This_DT suggests_VBZ that_IN the_DT
          55_CD /_NN 57_CD -_: kDa_NN human_JJ myocilin_NN doublet_NN is_VBZ due_JJ to_TO differential_NN
          glycosylation_NN and_CC that_IN the_DT site_NN of_IN N-_NNP linked_VBD glycosylation_NN
          on_IN human_JJ myocilin_NN is_VBZ Asn_NNP 57_CD ._.
          To_TO determine_VB the_DT effects_NNS of_IN deglycosylation_NN on_IN
          myocilin_NN ,_, we_PRP treated_VBD human_JJ ,_, monkey_NN ,_, and_CC rabbit_NN AH_NNP with_IN a_DT
          cocktail_NN of_IN glycosidases_NNS (_( N-_NNP and_CC O-_NNP linked_VBD )_) ._. Our_PRP$ results_NNS
          show_VBP that_IN the_DT upper_JJ band_NN of_IN human_NN and_CC monkey_NN myocilin_NN is_VBZ
          eliminated_VBN whereas_IN the_DT lower_JJR band_NN remains_VBZ unaltered_JJ (_( Fig_NNP ._.
          3_LS A_DT )_) ._. This_DT indicates_VBZ that_IN the_DT upper_JJ human_NN and_CC monkey_NN
          myocilin_NN band_NN is_VBZ glycosylated_JJ ._. In_IN addition_NN ,_, the_DT single_JJ
          rabbit_NN myocilin_NN band_NN shifted_VBD downward_JJ slightly_RB with_IN
          deglycosylation_NN ._. This_DT may_MD be_VB due_JJ to_TO removal_NN of_IN O-_NNP linked_VBD
          glycosylation_NN ._.
        
      
      
        Discussion_NNP
        We_PRP report_VBP the_DT cloning_VBG and_CC characterization_NN of_IN rabbit_NN
        myocilin_NN ._. Rabbit_NNP myocilin_NN is_VBZ highly_RB similar_JJ to_TO the_DT other_JJ
        myocilin_NN orthologs_NNS (_( Table_NNP 2_LS )_) and_CC contains_VBZ a_DT leucine_NN zipper_NN
        motif_NN encoded_JJ by_IN exon_NN 1_CD (_( Fig_NNP ._. 2_LS )_) ._. This_DT conservation_NN likely_JJ
        reflects_VBZ the_DT importance_NN of_IN the_DT leucine_NN zipper_NN motif_NN in_IN
        directing_VBG protein-protein_JJ interactions_NNS [_NN 34_CD 35_CD ]_NN ._. Many_JJ
        amino_JJ acid_NN mutations_NNS encoded_JJ in_IN the_DT olfactomedin_NN homology_NN
        domain_NN of_IN exon_NN 3_CD that_WDT are_VBP known_VBN to_TO cause_VB glaucoma_NN in_IN humans_NNS
        are_VBP also_RB conserved_JJ in_IN rabbit_NN myocilin_NN ._. In_IN fact_NN ,_, all_DT 31_CD
        amino_JJ acids_NNS (_( 34_CD missense_NN /_NN nonsense_NN mutations_NNS total_JJ )_) for_IN
        human_JJ myocilin_NN documented_VBN in_IN the_DT Human_NNP Gene_NNP Mutation_NNP
        Database_NNP
        http_NN :_: /_NN /_NN uwcmml_NN 1_CD s_VBZ ._. uwcm_NN ._. ac_NN ._. uk_NN /_NN uwcm_NN /_NN mg_NN /_NN search_NN /_NN 5584221_CD ._. htmlto_NN
        cause_NN glaucoma_NN are_VBP conserved_JJ in_IN rabbit_NN myocilin_NN (_( Fig_NNP
        2_LS )_) ._.
        Myocilin_NNP has_VBZ been_VBN shown_VBN to_TO be_VB secreted_JJ 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN by_IN several_JJ investigators_NNS [_NN 10_CD
        11_CD 12_CD 20_CD 21_CD 34_CD 36_CD 37_CD 38_CD ]_NN ._. Secreted_NNP proteins_NNS typically_RB
        contain_VBP a_DT 16_CD -_: 30_CD aa_NN signal_NN sequence_NN on_IN their_PRP$ N-_NNP terminus_JJ
        which_WDT directs_VBZ the_DT completion_NN of_IN protein_NN synthesis_NN across_IN
        the_DT ER_NNP membrane_NN ._. A_DT signal_NN peptidase_NN cleaves_NNS the_DT signal_NN
        sequence_NN and_CC the_DT trimmed_VBN protein_NN is_VBZ shuttled_VBN through_IN the_DT
        Golgi_NNP for_IN secretion_NN ._. We_PRP demonstrate_VBP the_DT functionality_NN of_IN
        the_DT N-_NNP terminal_NN signal_NN peptide_NN in_IN directing_VBG myocilin_NN
        secretion_NN ._. Deletion_NNP of_IN the_DT predicted_VBN N-_NNP terminal_NN signal_NN
        peptide_NN results_NNS in_IN loss_NN of_IN secretion_NN but_CC not_RB intracellular_NN
        appearance_NN (_( Fig_NNP ._. 3_LS B_NNP )_) ._.
        There_EX are_VBP conflicting_JJ reports_NNS on_IN whether_IN myocilin_NN is_VBZ
        glycosylated_JJ ._. Differential_NNP glycosylation_NN of_IN myocilin_NN has_VBZ
        been_VBN shown_VBN in_IN this_DT report_NN and_CC by_IN others_NNS [_NN 17_CD 20_CD 21_CD ]_NN to_TO
        account_VB for_IN the_DT appearance_NN of_IN a_DT 55_CD /_NN 57_CD -_: kDa_NN doublet_NN by_IN
        Western_JJ immunoblot_NN analysis_NN ._. In_IN contrast_NN ,_, Huang_NNP et_CC al_NN ._. [_NN 22_CD
        ]_NN report_NN that_DT myocilin_NN is_VBZ not_RB glycosylated_JJ ._. This_DT
        discrepancy_NN may_MD be_VB due_JJ to_TO technical_JJ reasons_NNS ._. Huang_NNP et_CC al_NN ._.
        did_VBD not_RB resolve_VB the_DT 55_CD /_NN 57_CD -_: kDa_NN doublet_NN using_VBG their_PRP$ SDS-PAGE_NNP
        system_NN and_CC only_RB detected_VBD a_DT 57_CD -_: kDa_NN human_JJ myocilin_NN band_NN ,_, so_IN
        any_DT deglycosylation_NN (_( PNGase_NNP F_NNP ,_, NANase_NNP II_NNP ,_, and_CC
        O-G_NNP lycosidase_NN )_) occurring_VBG would_MD be_VB difficult_JJ to_TO resolve_VB ._. A_DT
        positive_JJ control_NN was_VBD not_RB reported_VBN in_IN their_PRP$ deglycosylation_NN
        experiment_NN ,_, so_RB their_PRP$ conclusion_NN that_DT myocilin_NN is_VBZ not_RB
        glycosylated_JJ may_MD simply_RB be_VB due_JJ to_TO inactive_JJ glycosidase_NN ._. The_DT
        lack_NN of_IN glycosylation_NN seen_VBN in_IN the_DT 
        in_IN vitro_NN canine_JJ pancreatic_JJ microsomal_NN
        membrane_NN translation_NN experiment_NN may_MD again_RB be_VB due_JJ to_TO poor_JJ
        55_CD /_NN 57_CD -_: kDa_NN myocilin_NN doublet_NN resolution_NN or_CC the_DT inability_NN of_IN
        this_DT artificial_JJ system_NN to_TO faithfully_RB glycosylate_NN myocilin_NN ._.
        However_RB ,_, Caballero_NNP et_CC al_NN ._. was_VBD able_JJ to_TO detect_VB
        deglycosylation_NN affects_VBZ using_VBG similar_JJ methodology_NN [_NN 20_CD ]_NN
        ._.
        Nguyen_NNP et_CC al_NN ._. [_NN 10_CD ]_NN identified_VBD a_DT 66_CD -_: kDa_NN band_NN as_IN the_DT
        glycosylated_JJ and_CC major_JJ extracellular_NN form_NN of_IN human_JJ myocilin_NN
        and_CC not_RB the_DT upper_JJ band_NN in_IN the_DT 55_CD /_NN 57_CD -_: kDa_NN doublet_NN ._. These_DT
        authors_NNS claim_VBP that_IN the_DT lower_JJR band_NN of_IN the_DT unglycosylated_JJ
        55_CD /_NN 57_CD -_: kDa_NN doublet_NN is_VBZ due_JJ to_TO cleavage_NN of_IN the_DT N-_NNP terminal_NN 32_CD
        amino_JJ acid_NN signal_NN peptide_NN ._. In_IN our_PRP$ hands_NNS ,_, we_PRP do_VBP not_RB see_VB a_DT
        66_CD -_: kDa_NN band_NN on_IN our_PRP$ anti-myocilin_JJ Western_JJ blots_NNS ,_, even_RB using_VBG
        human_JJ aqueous_JJ humor_NN as_IN a_DT source_NN of_IN myocilin_NN ._. We_PRP provide_VBP
        evidence_NN that_IN the_DT upper_JJ band_NN of_IN the_DT 55_CD /_NN 57_CD -_: kDa_NN doublet_NN is_VBZ
        the_DT glycosylated_JJ form_NN of_IN myocilin_NN (_( Fig_NNP ._. 3_LS A_DT )_) ._. Another_DT group_NN
        has_VBZ also_RB reported_VBN the_DT 66_CD -_: kDa_NN band_NN using_VBG an_DT anti-myocilin_JJ
        antibody_NN different_JJ from_IN the_DT Nguyen_NNP et_CC al_NN ._. antibody_NN [_NN 14_CD ]_NN ._.
        The_DT reason_NN for_IN the_DT appearance_NN of_IN this_DT 66_CD -_: kDa_NN is_VBZ unclear_JJ ,_,
        but_CC may_MD be_VB due_JJ to_TO cross-reaction_JJ of_IN the_DT primary_JJ or_CC
        secondary_JJ antibody_NN with_IN another_DT protein_NN such_JJ as_IN albumin_NN ,_,
        which_WDT has_VBZ a_DT molecular_JJ weight_NN of_IN 65_CD -_: kDa_NN (_( GenPept_NNP accession_NN #_#
        NP_NNP __NN 000468_CD )_) ._. To_TO date_NN ,_, protein_NN sequence_NN data_NNS identifying_VBG the_DT
        66_CD -_: kDa_NN band_NN as_IN myocilin_NN has_VBZ not_RB been_VBN reported_VBN ._.
        Human_JJ myocilin_NN Asn_NNP 57_CD is_VBZ part_NN of_IN an_DT N-_NNP linked_VBD
        glycosylation_NN consensus_NN (_( NES_NNP )_) and_CC is_VBZ the_DT only_JJ residue_NN on_IN
        myocilin_NN predicted_VBD to_TO be_VB N-_NNP glycosylated_JJ ._. We_PRP provide_VBP both_DT
        site-directed_JJ mutagenesis_NNS (_( Fig_NNP ._. 3_LS B_NNP )_) and_CC deglycosylation_NN
        (_( Fig_NNP ._. 3_LS A_DT )_) evidence_NN that_IN the_DT upper_JJ band_NN of_IN the_DT 55_CD /_NN 57_CD -_: kDa_NN
        human_NN and_CC monkey_NN myocilin_NN doublet_NN is_VBZ the_DT glycosylated_JJ form_NN ._.
        The_DT increase_NN in_IN mobility_NN of_IN rabbit_NN myocilin_NN with_IN
        deglycosylation_NN (_( Fig_NNP ._. 3_LS A_DT )_) is_VBZ likely_JJ due_NN to_TO removal_NN of_IN
        O-_NNP linked_VBD glycosylation_NN ._. Analysis_NNP of_IN O-_NNP linked_VBD glycosylation_NN
        by_IN the_DT CBS_NNP NetOGlyc_NNP 2_CD ._. 0_CD Prediction_NNP Server_NNP
        http_NN :_: /_NN /_NN www_NN ._. cbs_NNS ._. dtu_NN ._. dk_NN /_NN services_NNS /_NN NetOGlyc_NNP /_NN identified_VBD two_CD
        unique_JJ (_( rabbit_NN Thr_NNP 93_CD and_CC Thr_NNP 267_CD )_) and_CC three_CD common_JJ (_( rabbit_NN
        Thr_NNP 66_CD ,_, Thr_NNP 263_CD ,_, and_CC Ser_NNP 45_CD )_) O-_NNP linked_VBD glycosylation_NN sites_NNS in_IN
        rabbit_NN vs_NNS ._. human_JJ /_NN monkey_NN myocilin_NN ._. The_DT additional_JJ O-_NNP linked_VBD
        glycosylation_NN sites_NNS in_IN rabbit_NN may_MD be_VB responsible_JJ for_IN the_DT
        mobility_NN shift_NN seen_VBN in_IN the_DT deglycosylation_NN experiment_NN and_CC
        the_DT relative_JJ diffusiveness_NNS of_IN the_DT rabbit_NN myocilin_NN band_NN ._.
        A_DT naturally_RB occuring_VBG Asn_NNP 57_CD Asp_NNP polymorphism_NN may_MD be_VB
        associated_VBN with_IN JOAG_NNP [_NN 39_CD ]_NN which_WDT ,_, if_IN truly_RB
        disease-associated_JJ ,_, would_MD suggest_VB the_DT functional_JJ importance_NN
        of_IN N-_NNP linked_VBD glycosylation_NN ._. N-_NNP linked_VBD glycosylation_NN is_VBZ known_VBN
        to_TO confer_VB stability_NN on_IN many_JJ extracellular_NN proteins_NNS [_NN 40_CD ]_NN ._.
        Myocilin_NNP is_VBZ similar_JJ to_TO fibronectin_NN (_( an_DT extracellular_NN matrix_NN
        protein_NN )_) in_IN that_IN both_DT a_DT glycosylated_JJ and_CC unglycosylated_JJ
        form_NN is_VBZ secreted_JJ from_IN the_DT cell_NN ._. The_DT unglycosylated_JJ form_NN of_IN
        fibronectin_NN is_VBZ more_RBR susceptible_JJ to_TO proteolytic_JJ degradation_NN
        than_IN the_DT glycosylated_JJ form_NN [_NN 41_CD ]_NN ._. It_PRP will_MD be_VB interesting_JJ
        to_TO determine_VB why_WRB two_CD forms_NNS of_IN myocilin_NN are_VBP secreted_JJ in_IN
        humans_NNS and_CC what_WP functionality_NN ,_, if_IN any_DT ,_, N-_NNP linked_VBD
        glycosylation_NN imparts_NNS on_IN human_JJ vs_NNS ._. rabbit_NN myocilin_NN ._.
        It_PRP is_VBZ still_RB unknown_JJ how_WRB myocilin_NN functions_NNS normally_RB and_CC
        pathophysiologically_RB ._. However_RB ,_, recent_JJ evidence_NN suggests_VBZ
        that_IN disease-causing_JJ myocilin_NN mutations_NNS are_VBP gain_NN of_IN
        function_NN ._. Disease-causing_NNP myocilin_NN mutants_NNS are_VBP less_RBR soluble_JJ
        in_IN Triton_NNP [_NN 16_CD ]_NN and_CC are_VBP retained_VBN by_IN the_DT cell_NN [_NN 12_CD ]_NN ._.
        Other_JJ studies_NNS have_VBP shown_VBN that_IN a_DT truncated_JJ form_NN of_IN myocilin_NN
        does_VBZ not_RB get_VB secreted_JJ [_NN 20_CD 21_CD ]_NN and_CC that_DT mouse_NN 
        MYOC_NNP knockouts_NNS are_VBP without_IN
        discernable_JJ phenotype_NN [_NN 42_CD ]_NN ._. Furthermore_RB ,_, a_DT human_JJ
        hemizygous_JJ individual_JJ containing_VBG an_DT interstitial_NN deletion_NN
        of_IN chromosome_NN 1_CD ,_, which_WDT encodes_NNS 
        MYOC_NNP ,_, was_VBD without_IN evidence_NN of_IN
        glaucoma_NN [_NN 43_CD ]_NN and_CC another_DT patient_NN homozygous_JJ for_IN a_DT
        severly_RB truncated_JJ form_NN of_IN myocilin_NN had_VBD no_DT evidence_NN of_IN
        glaucoma_NN [_NN 44_CD ]_NN or_CC other_JJ discernable_JJ phenotypes_NNS ._. This_DT
        suggests_VBZ that_IN 
        MYOC_NNP haploinsufficiency_NN is_VBZ not_RB
        causative_JJ for_IN glaucoma_NN and_CC that_DT myocilin_NN may_MD even_RB be_VB
        dispensable_JJ or_CC redundant_JJ in_IN normal_JJ human_JJ development_NN or_CC
        only_RB important_JJ when_WRB ocular_NN stress_NN occurs_VBZ ._.
      
      
        Conclusions_NNP
        Rabbit_NNP 
        MYOC_NNP encodes_NNS a_DT protein_NN highly_RB similar_JJ
        to_TO human_JJ 
        MYOC_NNP ._. Rabbit_NNP myocilin_NN is_VBZ secreted_JJ
        and_CC is_VBZ detected_VBN in_IN rabbit_NN aqueous_JJ humor_NN ._. Secretion_NNP of_IN
        myocilin_NN is_VBZ dependent_JJ on_IN an_DT 18_CD amino_JJ acid_NN N-_NNP terminal_NN signal_NN
        peptide_NN ._. Unlike_IN human_NN and_CC monkey_NN AH_NNP myocilin_NN ,_, rabbit_NN
        myocilin_NN does_VBZ not_RB undergo_VB canonical_JJ N-_NNP linked_VBN glycosylation_NN
        due_JJ to_TO the_DT substitution_NN of_IN a_DT serine_NN in_IN the_DT analogous_JJ human_JJ
        N-_NNP linked_VBD glycosylation_NN site_NN (_( N_NNP 57_CD )_) ._. Rabbits_NNP may_MD provide_VB an_DT
        in_IN vivo_NN system_NN for_IN modeling_VBG some_DT aspects_NNS of_IN glaucoma_NN ,_, such_JJ
        as_IN steroid_NN induced_VBD ocular_NN hypertension_NN [_NN 23_CD 24_CD 25_CD 26_CD 27_CD ]_NN
        and_CC the_DT gain-of-function_JJ hypothesis_NNS in_IN POAG_NNP [_NN 42_CD ]_NN ._.
      
      
        Methods_NNP
        
          Cloning_NNP of_IN rabbit_NN MYOC_NNP
          Total_NNP RNA_NNP was_VBD extracted_VBN from_IN rabbit_NN eye_NN and_CC heart_NN
          tissue_NN (_( Pel_NNP Freez_NNP )_) using_VBG Trizol_NNP (_( Invitrogen_NNP )_) ._. Primers_NNP
          derived_VBD from_IN conserved_JJ regions_NNS of_IN human_NN and_CC mouse_NN 
          MYOC_NNP (_( Table_NNP 1_CD ,_, primers_NNS
          Exon_NNP 1_CD F_NN /_NN Exon_NNP 1_CD R_NN )_) were_VBD used_VBN to_TO amplify_VB a_DT 250_CD -_: bp_NN section_NN of_IN
          rabbit_NN 
          MYOC_NNP exon_NN 1_CD (_( Fig_NNP ._. 1_LS ,_, nts_NNS 184_CD -_: 433_CD )_)
          by_IN PCR_NNP as_IN described_VBN [_NN 15_CD ]_NN ._. 5_CD '_POS and_CC 3_CD '_POS RACE_NNP (_( Invitrogen_NNP )_)
          was_VBD used_VBN to_TO obtain_VB the_DT 5_CD '_POS and_CC 3_CD '_POS cDNA_NN ends_NNS ._. Essentially_RB ,_,
          two_CD micrograms_NNS rabbit_NN total_JJ RNA_NNP was_VBD converted_VBN into_IN first_JJ
          strand_NN cDNA_NN with_IN adapter_NN primer_NN and_CC Superscript_NNP II_NNP
          reverse_VB transcriptase_NN ._. Primary_JJ and_CC nested_JJ 5_CD '_POS and_CC 3_CD '_POS RACE_NNP
          primers_NNS were_VBD all_DT designed_VBN within_IN the_DT 250_CD -_: bp_NN region_NN of_IN
          rabbit_NN 
          MYOC_NNP exon_NN 1_CD (_( Table_NNP 1_LS )_) ._. PCR_NNP products_NNS
          were_VBD subcloned_JJ into_IN TOPO_NNP ™_NN TA_NNP cloning_VBG vectors_NNS (_( Invitrogen_NNP )_)
          and_CC subjected_VBN to_TO cycle_NN sequencing_VBG (_( Division_NNP of_IN Molecular_NNP
          Transport_NNP ,_, Department_NNP of_IN Internal_NNP Medicine_NNP ,_, University_NNP of_IN
          Texas_NNP Southwestern_NNP Medical_NNP Center_NNP )_) ._.
          Due_JJ to_TO difficulties_NNS in_IN amplifying_VBG the_DT rabbit_NN 
          MYOC_NNP coding_VBG region_NN from_IN cDNA_NN ,_, we_PRP
          pieced_VBN together_RB the_DT entire_JJ contiguous_JJ open-reading_JJ frame_NN
          using_VBG rabbit_NN genomic_JJ DNA_NNP (_( Clontech_NNP ;_: New_NNP Zealand_NNP White_NNP )_) as_IN
          a_DT template_NN with_IN a_DT multi-step_JJ PCR_NNP /_NN ligation_NN process_NN ._. In_IN the_DT
          first_JJ step_NN ,_, exons_NNS 1_CD and_CC 2_CD were_VBD amplified_VBN from_IN genomic_JJ DNA_NNP
          with_IN primers_NNS P_NN 357_CD F_NN /_NN P_NN 368_CD R_NN to_TO exon_NN 1_CD and_CC P_NN 355_CD F_NN /_NN P_NN 365_CD R_NN to_TO
          exon_NN 2_CD ._. Primers_NNP P_NN 368_CD R_NN and_CC P_NN 355_CD F_NN directly_RB abut_NN each_DT other_JJ
          at_IN the_DT exon_NN 1_CD /_NN 2_CD boundary_NN ._. PCR_NNP amplification_NN was_VBD performed_VBN
          in_IN a_DT 50_CD ul_NN volume_NN with_IN the_DT PfuTurbo_NNP Hotstart_NNP DNA_NNP
          Polymerase_NNP system_NN (_( Stratagene_NNP )_) and_CC included_VBD 0_CD ._. 2_CD mM_NN dNTPs_NNS ,_,
          100_CD ng_NN each_DT primer_NN ,_, 2_CD ._. 5_CD units_NNS PfuTurbo_NNP DNA_NNP polymerase_NN ,_,
          100_CD ng_NN genomic_JJ DNA_NNP ,_, and_CC 1_CD X_NNP cloned_VBN Pfu_NNP DNA_NNP polymerase_NN
          reaction_NN buffer_NN ._. Cycling_NNP conditions_NNS consisted_VBD of_IN 2_CD min_NN at_IN
          95_CD °_NN C_NNP followed_VBN by_IN 15_CD cycles_NNS at_IN 95_CD °_NN C_NNP 30_CD sec_NN ,_, 60_CD °_NN C_NNP 30_CD sec_NN ,_,
          and_CC 72_CD °_NN C_NNP 1_CD min_NN in_IN a_DT Perkin_NNP Elmer_NNP 9700_CD thermalcycler_NN ._. PCR_NNP
          products_NNS were_VBD restriction_NN digested_VBN with_IN BamH_NNP 1_CD (_( exon_NN 1_LS )_) or_CC
          Not_RB 1_CD (_( exon_NN 2_LS )_) ,_, purified_JJ from_IN an_DT agarose_NN gel_NN by_IN Qiaquick_NNP
          extraction_NN (_( Qiagen_NNP )_) ,_, and_CC simultaneously_RB subcloned_JJ into_IN a_DT
          BamH_NNP 1_CD /_NN Not_RB 1_CD digested_VBN pcDNA_NN 3_CD (_( Invitrogen_NNP )_) vector_NN to_TO create_VB
          a_DT directional_NN clone_NN of_IN rabbit_NN 
          MYOC_NNP exons_NNS 1_CD and_CC 2_CD spliced_JJ together_RB
          (_( pcDNA_NN 3_CD ._. RbMYOCex_NNP 1_CD -_: 2_LS )_) ._. Sequence_NNP integrity_NN of_IN the_DT cloned_VBN
          DNA_NNP was_VBD verified_VBN by_IN cycle_NN sequencing_VBG and_CC restriction_NN
          digestion_NN ._.
          Exons_NNP 1_CD -_: 2_CD of_IN plasmid_NN pcDNA_NN 3_CD ._. RbMYOCex_NNP 1_CD -_: 2_CD was_VBD then_RB
          amplified_VBN with_IN primers_NNS P_NN 357_CD F_NN /_NN P_NN 370_CD R_NN and_CC exon_NN 3_CD was_VBD
          amplified_VBN from_IN genomic_JJ DNA_NNP with_IN primers_NNS P_NN 356_CD F_NN /_NN P_NN 356_CD R_NN ._.
          Primers_NNP P_NN 370_CD R_NN and_CC P_NN 356_CD F_NN directly_RB abut_NN each_DT other_JJ at_IN the_DT
          exon_NN 2_CD /_NN 3_CD boundary_NN ._. PCR_NNP was_VBD performed_VBN as_IN above_IN and_CC PCR_NNP
          products_NNS digested_VBN with_IN BamH_NNP 1_CD (_( exons_NNS 1_CD -_: 2_LS )_) or_CC Not_RB 1_CD (_( exon_NN 3_LS )_)
          and_CC processed_VBN /_NN cloned_VBN as_IN above_IN to_TO create_VB a_DT directional_NN
          clone_NN of_IN rabbit_NN 
          MYOC_NNP exons_NNS 1_CD -_: 2_CD and_CC 3_CD spliced_JJ
          together_RB (_( pcDNA_NN 3_CD ._. RbMYOCex_NNP 1_CD -_: 3_LS )_) ._. Plasmid_NNP DNA_NNP integrity_NN was_VBD
          confirmed_VBN by_IN restriction_NN analysis_NN and_CC cycle_NN
          sequencing_VBG ._.
        
        
          Sequence_NNP analysis_NN and_CC comparison_NN
          Alignment_NNP of_IN DNA_NNP sequence_NN contigs_NNS ,_, protein_NN sequences_NNS ,_,
          and_CC plasmid_NN DNA_NNP sequence_NN /_NN construction_NN was_VBD performed_VBN with_IN
          Vector_NNP NTI_NNP 7_CD ._. 1_CD software_NN (_( Informax_NNP )_) ._.
        
        
          Construction_NNP of_IN human_JJ MYOCmutants_NNP
          Human_NNP 
          MYOC_NNP cDNA_NN was_VBD cloned_VBN into_IN the_DT
          pcDNA_NN 3_CD (_( Invitrogen_NNP )_) mammalian_JJ expression_NN vector_NN as_IN
          described_VBN [_NN 12_CD ]_NN ._. Human_NNP myocilin_NN signal_NN sequence_NN
          deletions_NNS were_VBD generated_VBN by_IN PCR_NNP ._. A_DT 5_CD '_POS PCR_NNP primer_NN ,_, with_IN a_DT
          5_CD '_POS HindIII_NNP site_NN added_VBD ,_, was_VBD designed_VBN to_TO eliminate_VB either_CC
          the_DT first_JJ 42_CD -_: (_( P_NN 235_CD ;_: ΔN_NN 14_CD )_) or_CC 96_CD -_: (_( P_NN 236_CD ;_: ΔN_NN 32_CD )_)
          nucleotides_NNS of_IN the_DT human_JJ 
          MYOC_NNP ORF_NNP and_CC used_VBN in_IN conjunction_NN
          with_IN a_DT 3_CD '_POS PCR_NNP primer_NN (_( P_NN 237_CD )_) covering_VBG the_DT internal_JJ Bsu_NNP 36_CD I_PRP
          restriction_NN site_NN (_( Table_NNP 1_LS )_) ._. Primer_NNP P_NN 236_CD replaced_VBD the_DT
          first_JJ 32_CD amino_JJ acid_NN codons_NNS with_IN a_DT methionine_NN codon_NN ._. PCR_NNP
          and_CC processing_NN were_VBD as_IN described_VBN above_IN with_IN the_DT exception_NN
          that_IN the_DT 5_CD '_POS human_JJ 
          MYOC_NNP deletion_NN products_NNS were_VBD cloned_VBN
          into_IN a_DT HindIII_NNP /_NN Bsu_NNP 36_CD I_PRP digested_VBN pcDNA_NN 3_CD ._. hMYOC_NN wild-type_JJ
          vector_NN ._.
          Substitution_NNP of_IN human_JJ myocilin_NN Asn_NNP 57_CD with_IN Ser_NNP was_VBD
          accomplished_VBN using_VBG the_DT QuickChange_NNP XL_NNP Site-_NNP Directed_NNP
          Mutagenesis_NNP kit_NN (_( Stratagene_NNP )_) according_VBG to_TO the_DT
          manufacturer_NN 's_POS instructions_NNS ._. Primer_NNP pair_NN P_NN 316_CD F_NN /_NN P_NN 316_CD R_NN was_VBD
          designed_VBN to_TO replace_VB the_DT Asn_NNP 57_CD A_DT 
          A_DT T_NN codon_NN with_IN the_DT Ser_NNP A_DT 
          G_NNP T_NN codon_NN (_( Table_NNP 1_LS )_) ._. The_DT entire_JJ
          mutated_VBN cDNA_NN was_VBD sequence_NN verified_VBN and_CC subcloned_JJ into_IN a_DT
          fresh_JJ pcDNA_NN 3_CD vector_NN to_TO avoid_VB non-specific_JJ Taq_NNP DNA_NNP
          polymerase_NN errors_NNS ._. Proper_JJ cloning_VBG was_VBD verified_VBN by_IN
          restriction_NN digestion_NN analysis_NN and_CC sequencing_VBG ._.
        
        
          Cell_NNP culture_NN and_CC transfection_NN
          GTM_NNP 66_CD cells_NNS were_VBD derived_VBN from_IN a_DT 92_CD -_: year_NN old_JJ woman_NN with_IN
          glaucoma_NN and_CC were_VBD cultured_JJ in_IN low_JJ glucose_NN DMEM_NNP (_( HyClone_NNP
          Laboratories_NNPS )_) with_IN 10_CD %_NN FBS_NNP (_( HyClone_NNP Laboratories_NNPS )_) and_CC
          antibiotics_NNS (_( Invitrogen_NNP )_) as_IN described_VBN [_NN 11_CD 17_CD ]_NN ._. Cells_NNP
          were_VBD transfected_JJ with_IN Lipofectamine_NNP 2000_CD reagent_NN
          according_VBG to_TO the_DT manufacturers_NNS recommendations_NNS
          (_( Invitrogen_NNP )_) ._. Transfected_NNP plasmid_NN DNA_NNP included_VBD wild-type_JJ
          human_JJ 
          MYOC_NNP (_( pcDNA_NN 3_CD ._. hMYOC_NN ;_: [_NN 12_CD ]_NN )_) ,_,
          wild-type_JJ rabbit_NN 
          MYOC_NNP (_( pcDNA_NN 3_CD ._. RbMYOC_NNP ._. ex_FW 1_CD -_: 3_LS )_) ,_,
          N-_NNP terminal_NN 14_CD amino_JJ acid_NN deleted_VBN human_JJ 
          MYOC_NNP (_( pcDNA_NN 3_CD ._. hMYOC_NN ._. ΔN_NN 14_CD )_) ,_,
          N-_NNP terminal_NN 32_CD amino_JJ acid_NN deleted_VBN human_JJ 
          MYOC_NNP (_( pcDNA_NN 3_CD ._. hMYOC_NN ._. ΔN_NN 32_CD )_) ,_, or_CC N_NNP 57_CD S_NNP
          human_JJ 
          MYOC_NNP (_( pcDNA_NN 3_CD ._. hMYOC_NN ._. N_NNP 57_CD S_NNP )_) ._. Cells_NNP
          were_VBD switched_VBN to_TO serum-free_JJ media_NNS 24_CD h_NN post-transfection_JJ
          and_CC media_NNS or_CC cell_NN lysates_NNS were_VBD collected_VBN after_IN overnight_JJ
          incubation_NN ._. Equivalent_NNP cell_NN lysate_NN protein_NN amounts_NNS (_( 5_CD μg_NN )_)
          were_VBD loaded_VBN for_IN reduced_VBN SDS-PAGE_NNP analysis_NN (_( Fig_NNP ._. 3_LS B_NNP )_) ._. Cell_NNP
          media_NNS was_VBD not_RB concentrated_VBN and_CC was_VBD loaded_VBN at_IN 16_CD ul_NN per_IN
          lane_NN in_IN Fig_NNP ._. 3_LS B_NNP ._.
        
        
          Aqueous_NNP humor_NN samples_NNS
          All_DT experimental_JJ animals_NNS used_VBN in_IN this_DT study_NN were_VBD
          treated_VBN in_IN compliance_NN with_IN the_DT Association_NNP for_IN Research_NNP
          in_IN Vision_NNP and_CC Ophthalmology_NNP (_( ARVO_NNP )_) resolution_NN on_IN the_DT use_NN
          of_IN animals_NNS in_IN research_NN ._. Rabbit_NNP aqueous_JJ humor_NN samples_NNS
          (_( 135_CD -_: 190_CD μl_NN )_) were_VBD taken_VBN from_IN anesthetized_JJ New_NNP Zealand_NNP
          Albino_NNP (_( NZA_NNP )_) rabbits_NNS and_CC mixed_VBN with_IN protease_NN inhibitor_NN
          cocktail_NN (_( Complete_JJ ;_: Roche_NNP )_) to_TO prevent_VB myocilin_NN
          degradation_NN ._. Human_NNP aqueous_JJ humor_NN samples_NNS were_VBD obtained_VBN as_RB
          previously_RB described_VBD [_NN 12_CD ]_NN ._. The_DT equivalent_NN of_IN 4_CD μl_NN AH_NNP
          was_VBD used_VBN per_IN lane_NN in_IN Fig_NNP ._. 3_LS A_DT ._.
        
        
          Immunoblot_NNP analysis_NN
          Cells_NNP were_VBD rinsed_JJ with_IN PBS_NNP and_CC solubilized_JJ in_IN a_DT
          commercial_JJ mammalian_JJ extraction_NN buffer_NN (_( M-P_NNP er_UH ™_NN ;_: Pierce_NNP ,_,
          Rockford_NNP ,_, IL_NNP )_) supplemented_JJ with_IN a_DT protease_NN inhibitor_NN
          cocktail_NN (_( Complete_JJ ;_: Roche_NNP )_) followed_VBN by_IN centrifugation_NN at_IN
          12_CD ,_, 000_CD ×_NN g_SYM for_IN 5_CD min_NN ._. Protein_NNP concentration_NN of_IN the_DT
          supernatant_NN was_VBD determined_VBN with_IN Coomassie_NNP Plus_NNP Protein_NNP
          Assay_NNP Reagent_NNP (_( Pierce_NNP )_) ._. Cell_NNP extracts_NNS were_VBD stored_VBN at_IN
          -_: 20_CD °_NN C_NNP ._.
          Aqueous_NNP humor_NN ,_, cell_NN media_NNS ,_, and_CC cell_NN extracts_NNS were_VBD
          analyzed_VBN using_VBG pre-cast_JJ Criterion_NNP 7_CD ._. 5_CD %_NN Tris-_NNP HCl_NNP
          polyacrylamide_NN gels_NNS (_( Bio-_NNP Rad_NNP )_) and_CC the_DT Bio-_NNP Rad_NNP
          electrophoresis_NNS system_NN (_( Bio-_NNP Rad_NNP )_) ._. Proteins_NNPS were_VBD
          electroblotted_JJ to_TO Hybond-_NNP P_NN PVDF_NNP membranes_NNS (_( Amersham_NNP
          Pharmacia_NNP Biotech_NNP )_) ,_, blocked_VBN with_IN gelatin_NN ,_, and_CC probed_JJ with_IN
          affinity_NN purified_JJ rabbit_NN anti-human_JJ myocilin_NN antibody_NN 129_CD
          (_( AB_NNP 129_CD ;_: generated_VBN to_TO human_JJ myocilin_NN amino_JJ acids_NNS 156_CD -_: 171_CD )_)
          [_NN 12_CD 17_CD ]_NN and_CC an_DT anti-rabbit_JJ IgG_NNP secondary_JJ antibody_NN
          (_( Amersham_NNP )_) ._. Immunoreactivity_NNP was_VBD detected_VBN with_IN the_DT ECL_NNP
          Plus_NNP detection_NN system_NN (_( Amersham_NNP )_) ._. Blots_NNP were_VBD exposed_VBN to_TO
          BioMax_NNP MR_NNP film_NN (_( Eastman_NNP Kodak_NNP )_) and_CC scanned_JJ with_IN a_DT HP_NNP
          ScanJet_NNP 7400_CD c_SYM scanner_NN (_( Hewlett_NNP Packard_NNP )_) ._.
        
        
          Deglycosylation_NNP of_IN aqueous_JJ humor_NN myocilin_NN
          Aqueous_NNP humor_NN from_IN human_JJ ,_, monkey_NN and_CC rabbit_NN was_VBD
          subjected_VBN to_TO deglycosylation_NN with_IN a_DT mixture_NN of_IN N-_NNP linked_VBD
          and_CC O-_NNP linked_VBD glycosidases_NNS (_( PNGase_NNP F_NNP ,_, sialidase_NN ,_,
          β-galactosidase_JJ ,_, glucosaminidase_NN and_CC O-_NNP glycosidase_NN )_) using_VBG
          the_DT Enzymatic_NNP CarboRelease_NNP Kit_NNP according_VBG to_TO the_DT
          manufacturers_NNS instructions_NNS (_( QA-Bio_NNP )_) ._. AH_NNP samples_NNS in_IN buffer_NN
          were_VBD boiled_VBD for_IN 5_CD min_NN in_IN the_DT presence_NN of_IN denaturant_NN
          followed_VBN by_IN incubation_NN for_IN 3_CD hr_NN at_IN 37_CD °_NN C_NNP with_IN the_DT
          glycosidase_NN mixture_NN ._. NuPAGE_NNP sample_NN buffer_NN (_( Invitrogen_NNP )_)
          was_VBD added_VBN to_TO stop_VB the_DT reaction_NN ,_, samples_NNS were_VBD heated_JJ for_IN
          10_CD min_NN at_IN 70_CD °_NN C_NNP and_CC subjected_VBN to_TO NuPAGE_NNP electrophoresis_NNS on_IN
          10_CD %_NN NuPAGE_NNP gels_NNS (_( Invitrogen_NNP )_) ._. Samples_NNP were_VBD transferred_VBN to_TO
          PVDF_NNP ,_, immunoblotted_JJ versus_CC AB_NNP 129_CD ,_, and_CC developed_VBD using_VBG ECL_NNP
          Plus_NNP ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        AS_NNP carried_VBD out_RP the_DT clone_NN isolation_NN and_CC characterization_NN ,_,
        sequence_NN comparison_NN ,_, plasmid_NN construction_NN ,_, and_CC drafted_VBD the_DT
        manuscript_NN ._. NJ_NNP carried_VBD out_RP the_DT cell_NN culture_NN ,_, transfections_NNS
        and_CC immunoblot_NN analyses_NNS ._. RS_NNP generated_VBD preliminary_JJ sequence_NN
        data_NNS for_IN rabbit_NN 
        MYOC_NNP and_CC a_DT preliminary_JJ manuscript_NN
        draft_NN ._. TS_NNP provided_VBD computer_NN analysis_NN /_NN modeling_NN of_IN myocilin_NN ._.
        AL_NNP oversaw_VBD the_DT work_NN of_IN RS_NNP ._. ES_NNP oversaw_VBD the_DT work_NN of_IN AL_NNP and_CC
        RS_NNP ._. AC_NNP conceived_VBD of_IN the_DT study_NN ,_, helped_VBD draft_NN the_DT manuscript_NN ,_,
        and_CC oversaw_VBD the_DT work_NN of_IN AS_NNP ,_, NJ_NNP ,_, and_CC TS_NNP ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
